Effects of apolipoprotein A5 haplotypes on the ratio of triglyceride to high-density lipoprotein cholesterol and the risk for metabolic syndrome in Koreans

Lipids in Health and Disease

Kwang Hoon Song¹  Ah Yeon Park²  Hyunjoo Yu²  Seongwon Cha² 

[1] SME Partnership Center, Korea Institute of Oriental Medicine, 1672 Yuseongdae-ro, Yuseong-gu, Daejeon 305-811, Republic of Korea;KM Health Technology Research Group, Medical Research Division, Korea Institute of Oriental Medicine, 1672 Yuseongdae-ro, Yuseong-gu, Daejeon 305-811, Republic of Korea

关键词: Polymorphism;    Metabolic syndrome;    HDL cholesterol;    Triglyceride;    Triglceride-to-HDL cholesterol ratio;    Haplotype;    ZNF259;    APOA5;   

Others  :  811108
DOI  :  10.1186/1476-511X-13-45

 received in 2014-01-02, accepted in 2014-03-04,  发布年份 2014

【 摘 要 】

Background

Single-nucleotide polymorphisms (SNPs) around the apolipoprotein A5 gene (APOA5) have pleiotropic effects on the levels of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C). APOA5 SNPs have also been associated with metabolic syndrome (MS). Here, we constructed haplotypes with SNPs spanning APOA5 and ZNF259, which are approximately 1.3 kb apart, to perform association analyses with the risk for MS and the levels of TG and HDL-C in terms of a TG:HDL-C ratio.

Methods

The effects of three constructed haplotypes (TAA, CGG, and CGA, in the order of rs662799, rs651821, and rs6589566) on the TG:HDL-C ratio and MS were estimated using multiple regression analyses in 2,949 Koreans and in each gender separately (1,082 men and 1,867 women).

Results

The haplotypes, CGG and CGA, were associated with the TG:HDL-C ratio and the risk of MS development in both genders. That is, the minor alleles of the rs662799 and rs651821 in APOA5, irrespective of which allele was present at rs6589566, had the marked effects. Interestingly, a C–G–A haplotype at these three SNPs had the most marked effects on the TG:HDL-C ratio and the risk of MS development in women.

Conclusions

We have identified the novel APOA5-ZNF259 haplotype manifesting sex-dependent effects on elevation of the TG:HDL-C ratio as well as the increased risk for MS.

【 授权许可】

   
2014 Cha et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Song KH, Cha S, Yu SG, Yu H, Oh SA, Kang NS: Association of Apolipoprotein A5 Gene -1131T>C Polymorphism with the Risk of Metabolic Syndrome in Korean Subjects. Biomed Research International 2013, 2013:585134.
• [2]Kraja AT, Vaidya D, Pankow JS, Goodarzi MO, Assimes TL, Kullo IJ, Sovio U, Mathias RA, Sun YV, Franceschini N, Absher D, Li G, Zhang Q, Feitosa MF, Glazer NL, Haritunians T, Hartikainen AL, Knowles JW, North KE, Iribarren C, Kral B, Yanek L, O’Reilly PF, McCarthy MI, Jaquish C, Couper DJ, Chakravarti A, Psaty BM, Becker LC, Province MA, et al.: A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes 2011, 60:1329-1339.
• [3]Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, et al.: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009, 41:56-65.
• [4]Povel CM, Boer JM, Reiling E, Feskens EJ: Genetic variants and the metabolic syndrome: a systematic review. Obes Rev 2011, 12:952-967.
• [5]Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC: Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002, 11:3031-3038.
• [6]Olivier M, Wang X, Cole R, Gau B, Kim J, Rubin EM, Pennacchio LA: Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 2004, 83:912-923.
• [7]Choi JR, Nam CM, Kang DR, Eom SM, Lee HJ, Park CM, Im JW, Jang Y: DNA polymorphisms and haplotypes of apolipoprotein A5's attribution to the plasma triglyceride levels in Koreans. Yonsei Med J 2007, 48:609-618.
• [8]Chien KL, Chen MF, Hsu HC, Su TC, Chang WT, Lee CM, Lee YT: Genetic association study of APOA1/C3/A4/A5 gene cluster and haplotypes on triglyceride and HDL cholesterol in a community-based population. Clin Chim Acta 2008, 388:78-83.
• [9]Matsunaga A, Arishima H, Niimura H, Zhang B, Uehara Y, Ohwaki K, Morita M, Hayashida K, Saku K: Strong linkage disequilibrium and association of -1131T>C and c.553G>T polymorphisms of the apolipoprotein A5 gene with hypertriglyceridemia in a Japanese population. Circ J 2007, 71:746-752.
• [10]Grallert H, Sedlmeier EM, Huth C, Kolz M, Heid IM, Meisinger C, Herder C, Strassburger K, Gehringer A, Haak M, Giani G, Kronenberg F, Wichmann HE, Adamski J, Paulweber B, Illig T, Rathmann W: APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res 2007, 48:2614-2621.
• [11]Kisfali P, Mohas M, Maasz A, Polgar N, Hadarits F, Marko L, Brasnyo P, Horvatovich K, Oroszlan T, Bagosi Z, Bujtor Z, Gasztonyi B, Rinfel J, Wittmann I, Melegh B: Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2010, 20:505-511.
• [12]Qi L, Liu S, Rifai N, Hunter D, Hu FB: Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Atherosclerosis 2007, 192:204-210.
• [13]Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
• [14]Forte TM, Shu X, Ryan RO: The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res 2009, 50(Suppl):S150-155.
• [15]Galcheva-Gargova Z, Konstantinov KN, Wu IH, Klier FG, Barrett T, Davis RJ: Binding of zinc finger protein ZPR1 to the epidermal growth factor receptor. Science 1996, 272:1797-1802.
• [16]Kawakami A, Tanaka A, Chiba T, Nakajima K, Shimokado K, Yoshida M: Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation. Circulation 2003, 108:2679-2688.
• [17]Berrahmoune H, Lamont JV, Herbeth B, Lambert D, Masson C, McPhillips M, Fitzgerald PS, Visvikis-Siest S: Association between EGF and lipid concentrations: a benefit role in the atherosclerotic process? Clin Chim Acta 2009, 402:196-198.
• [18]Ken-Dror G, Goldbourt U, Dankner R: Different effects of apolipoprotein A5 SNPs and haplotypes on triglyceride concentration in three ethnic origins. J Hum Genet 2010, 55:300-307.
• [19]Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart AF, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, et al.: Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580.
• [20]Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992, 70:733-737.
• [21]Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997, 96:2520-2525.
• [22]da Luz PL, Favarato D, Faria-Neto JR Jr, Lemos P, Chagas AC: High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 2008, 63:427-432.
• [23]McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM: Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005, 96:399-404.
• [24]Salazar MR, Carbajal HA, Espeche WG, Dulbecco CA, Aizpurua M, Marillet AG, Echeverria RF, Reaven GM: Relationships among insulin resistance, obesity, diagnosis of the metabolic syndrome and cardio-metabolic risk. Diab Vasc Dis Res 2011, 8:109-116.
• [25]McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003, 139:802-809.
• [26]Cha S, Yu H, Kim JY: Bone mineral density-associated polymorphisms are associated with obesity-related traits in Korean adults in a sex-dependent manner. PLoS One 2012, 7:e53013.
• [27]Expert Panel on Detection E: Treatment of High Blood Cholesterol in A: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
• [28]WHO/IASO/IOTF: The Asia-Pacific perspective: redefining obesity and its treatment. Melbourne: Health Communications Australia; 2000.
• [29]Jeong S, Yu H, Lee Y, Kim JY: SNP genotyping through the melting analysis of unlabelled oligonucleotide applied on dilute PCR amplicon. J Biotechnol 2011, 154:321-325.
• [30]Kim BY, Jin HJ, Kim JY: Genome-wide association analysis of Sasang constitution in the Korean population. J Altern Complement Med 2012, 18:262-269.
• [31]Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
• [32]Stephens M, Scheet P: Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005, 76:449-462.
• [33]Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.